News headlines about Cara Therapeutics (NASDAQ:CARA) have been trending positive on Tuesday, according to Accern Sentiment. The research firm scores the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cara Therapeutics earned a daily sentiment score of 0.32 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 68 out of 100, meaning that recent media coverage is likely to have an effect on the stock’s share price in the next several days.
Here are some of the news headlines that may have impacted Accern’s rankings:
- Here’s Why Cara Therapeutics, Inc. (CARA) Trending These Days (cromaplus.net)
- 3 Stocks to Watch on Wednesday: Square Inc (SQ), Cara Therapeutics Inc (CARA) and Healthcare Services Group, Inc … – Investorplace.com (investorplace.com)
- ETFs with exposure to CARA Therapeutics, Inc. : July 14, 2017 (finance.yahoo.com)
- Take a look at Price Move: Cara Therapeutics, Inc. (CARA) (footballhebdo.com)
- Factors to Note Before Buying Cara Therapeutics Inc. (CARA) (healthcaremenu.net)
A number of brokerages have recently commented on CARA. Piper Jaffray Companies reissued a “buy” rating and issued a $27.00 price target on shares of Cara Therapeutics in a report on Saturday, July 1st. Canaccord Genuity set a $25.00 price target on shares of Cara Therapeutics and gave the stock a “buy” rating in a report on Saturday, July 1st. HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Cara Therapeutics in a report on Monday, April 24th. Royal Bank Of Canada reduced their target price on shares of Cara Therapeutics from $32.00 to $31.00 and set an “outperform” rating on the stock in a report on Monday, May 15th. Finally, Vetr lowered shares of Cara Therapeutics from a “strong-buy” rating to a “buy” rating and set a $21.73 target price on the stock. in a report on Wednesday, June 21st. Four research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $25.68.
Shares of Cara Therapeutics (NASDAQ CARA) opened at 15.43 on Tuesday. The stock has a 50 day moving average of $18.44 and a 200 day moving average of $15.55. The stock’s market capitalization is $501.58 million. Cara Therapeutics has a 52-week low of $4.75 and a 52-week high of $28.50.
Cara Therapeutics (NASDAQ:CARA) last released its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.73) by $0.08. The firm had revenue of $0.91 million during the quarter, compared to analyst estimates of $0.11 million. The company’s revenue for the quarter was up 12900.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.39) earnings per share. Analysts forecast that Cara Therapeutics will post ($2.44) earnings per share for the current year.
In related news, Director Dean Slagel sold 250,000 shares of the company’s stock in a transaction on Thursday, June 29th. The stock was sold at an average price of $25.87, for a total transaction of $6,467,500.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Corporate insiders own 7.50% of the company’s stock.
About Cara Therapeutics
Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.
Receive News & Ratings for Cara Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.